Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Average Target Price from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $9.00.

A number of equities analysts have recently weighed in on PYXS shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 target price (down previously from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and set a $5.00 price target (down previously from $7.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. William Blair cut Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Finally, Stephens began coverage on Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 target price for the company.

Pyxis Oncology Stock Down 4.5 %

Shares of Pyxis Oncology stock opened at $1.50 on Friday. Pyxis Oncology has a 12-month low of $1.39 and a 12-month high of $6.85. The firm has a market capitalization of $89.21 million, a PE ratio of -1.46 and a beta of 1.06. The stock’s fifty day moving average is $1.64 and its 200-day moving average is $2.93.

Insider Activity

In related news, CFO Pamela Ann Connealy purchased 88,850 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was acquired at an average price of $1.96 per share, with a total value of $174,146.00. Following the completion of the acquisition, the chief financial officer now directly owns 1,199,143 shares in the company, valued at approximately $2,350,320.28. This trade represents a 8.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 9.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Pyxis Oncology

A number of institutional investors have recently bought and sold shares of the business. Intech Investment Management LLC bought a new position in Pyxis Oncology in the third quarter valued at approximately $55,000. SG Americas Securities LLC acquired a new position in Pyxis Oncology during the third quarter worth $58,000. The Manufacturers Life Insurance Company bought a new stake in Pyxis Oncology in the 2nd quarter valued at $65,000. MetLife Investment Management LLC boosted its position in Pyxis Oncology by 41.1% during the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new position in Pyxis Oncology during the third quarter worth $107,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.